Citi: The target price of "buy" rating for minimally invasive medical services is reduced to HK $21

Zhitong Finance

2.86W people concern

Connect to global capital markets.

Citi: The target price of "buy" rating for minimally invasive medical service is reduced to HK $21

Zhitong Finance Network 2024-06-14 17:12 7.7w Read

According to the research report released by Citigroup Minimally invasive medical treatment (00853) According to the latest guidance of the management and recent sales trend, the bank fine tuned its earnings per share forecast. It is expected that earnings per share in 2024 will increase by 59.4% and earnings per share in 2025 will increase by 43%, reflecting the company's strict cost control trend. The target price was lowered from HK $25 to HK $21, reflecting the downward revision of the valuation of the heart valve business, and was rated as "buy".

Source: Zhitong Financial Network

Zhitong Finance Insurance

Important: This article only represents the author's personal view, and does not represent Leju's financial position. The purpose of this article is to collect and provide information to meet the information needs of users, not for commercial or profitable purposes. If any unit or individual believes that the source of this document is marked incorrectly, or is suspected of infringing its intellectual property rights and other related rights, please provide relevant information such as identity certificate, ownership certificate and detailed infringement proof, click【 Contact customer service 】Or send an email to【 ljcj@leju.com 】, we will review and handle in a timely manner.

Leju Financial Selection

Stealing area

Tel: 400-606-6969 Mail: ljcj@leju.com

Hang Seng Pharmaceutical ETF (159892) fell by more than 2%, led by minimally invasive medical treatment

The interface has Lianyun 05-21

Nomura: The target price for the "neutral" rating of minimally invasive medical treatment is reduced to HK $6.71

Zhitong Finance Network 04-09

Xinhong Life obtained tens of millions of Pre-A rounds of financing, and the founder Wu Changsheng was the project leader of minimally invasive coronary star products

Rui Finance 04-07

The share price of minimally invasive medical fell by 90%. Chairman Chang Zhaohua said that 12 subsidiaries would be split and listed

Rui Finance 04-07

Minimally invasive medical services fell by more than 4% in the session, and the net loss in 2023 is expected to be no more than 580 million dollars

Rui Finance 03-06

24-hour popular articles

Latest articles

More original

Shen Tianqing misappropriated hundreds of millions of funds from Jiayuan's service, and the veteran of 16 years "carried the pot" and left

original Leju Finance 20:26

Furui: maintain the target price of Zhongtong Express - W "buy" rating raised to HK $222

Zhitong Finance Network 18:50

DBS: raise the target price of China Hongqiao to HK $13.9 to "buy"

Zhitong Finance Network 18:50

Retailers exceed the Jianghu | Since 2020, the collective declining income will not be the loss of Lianhua Supermarket for ten consecutive years, and the huge loss of Gaoxin Retail in fiscal year 2024 will be 1.605 billion

Sina Finance 18:36

Retailers surpass the Jianghu | In the first half of 2024 * ST Bugao's sales expense rate reaches 33%, and Gaoxin's retail sales expense reaches 18.2 billion yuan, but it is hard to avoid huge losses

Top search

Search History empty

Citi: The target price of "buy" rating for minimally invasive medical service is reduced to HK $21

Stealing area

Related articles

Hang Seng Pharmaceutical ETF (159892) fell by more than 2%, led by minimally invasive medical treatment

Nomura: The target price for the "neutral" rating of minimally invasive medical treatment is reduced to HK $6.71

Xinhong Life obtained tens of millions of Pre-A rounds of financing, and the founder Wu Changsheng was the project leader of minimally invasive coronary star products

The share price of minimally invasive medical fell by 90%. Chairman Chang Zhaohua said that 12 subsidiaries would be split and listed

Minimally invasive medical services fell by more than 4% in the session, and the net loss in 2023 is expected to be no more than 580 million dollars

24-hour popular articles

Latest articles

Shen Tianqing misappropriated hundreds of millions of funds from Jiayuan's service, and the veteran of 16 years "carried the pot" and left

Furui: maintain the target price of Zhongtong Express - W "buy" rating raised to HK $222

DBS: raise the target price of China Hongqiao to HK $13.9 to "buy"

Retailers exceed the Jianghu | Since 2020, the collective declining income will not be the loss of Lianhua Supermarket for ten consecutive years, and the huge loss of Gaoxin Retail in fiscal year 2024 will be 1.605 billion

Retailers surpass the Jianghu | In the first half of 2024 * ST Bugao's sales expense rate reaches 33%, and Gaoxin's retail sales expense reaches 18.2 billion yuan, but it is hard to avoid huge losses

comment

Go to Leju Finance APP to view the original text and have a better experience

follow

original

data

List